

Osimertinib AURA3

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



QoL data pending



Serious and disabling adverse effects



Less serious and disabling adverse events observed



Other adjustments



Osimertinib AURA3

SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Thoracic Malignancies

Therapeutic Indication: Osimertinib used as monotherapy for the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC.

Experimental Arm: Osimertinib

Control Arm: Platinum/pemetrexed



